Biopharmaceutical innovation is accelerating as companies integrate AI and digital workflows to streamline compound design, synthesis, and testing. Ginkgo Bioworks, Inductive Bio, and Tangible Scientific formed a strategic partnership to combine rapid ADME profiling, AI-driven chemistry design, and compound management into an integrated, model-driven drug discovery workflow. Meanwhile, generative AI models developed at MIT have generated novel antibiotic structures from scratch, showcasing AI's potential in identifying new therapeutics. Additionally, Vantai's more than $1 billion collaboration with Halda Therapeutics aims to leverage generative AI for next-generation small molecule drug discovery, especially targeting challenging GPCRs relevant to obesity and cardiometabolic diseases.